Holdings of Propel Bio Management, LLC
33 declared positions · as of Mar 31, 2026
Original filing · Ten largest lines: 61.8 % of the equity sleeve
Sector breakdown
Titelia classification, company by company. The unattributed share stays visible.
Currency breakdown
The quoted currency of each line, as declared.
Country breakdown
- US 94.5 %
- GB 2.8 %
- FR 2.7 %
Shares computed on the equity sleeve.
| Rank | Country | Lines | Value | Share |
|---|
| 1 | US | 31 | 139.9M $ | 94.52 % |
| 2 | GB | 1 | 4.1M $ | 2.78 % |
| 3 | FR | 1 | 4M $ | 2.70 % |
Positions
| Rank | Company | Shares | Value | Weight |
|---|
| 1 | Plains GP Holdings LP | 1,272,360 | 30.2M $ | |
| 2 | ACHIEVE LIFE SCIENCES INC | 3,786,425 | 11.4M $ | |
| 3 | Phathom Pharmaceuticals Inc | 841,272 | 9.4M $ | |
| 4 | Delcath Systems Inc | 979,698 | 9.2M $ | |
| 5 | Corcept Therapeutics Inc | 147,828 | 6M $ | |
| 6 | Abeona Therapeutics Inc | 1,329,899 | 6M $ | |
| 7 | Vor BioPharma Inc | 314,543 | 5.6M $ | |
| 8 | Kyverna Therapeutics Inc | 644,421 | 5.6M $ | |
| 9 | Celldex Therapeutics Inc | 131,364 | 4.1M $ | |
| 10 | Compass Pathways plc | 742,049 | 4.1M $ | |
| 11 | Viridian Therapeutics Inc | 210,163 | 4.1M $ | |
| 12 | Inventiva SACA | 724,678 | 4M $ | |
| 13 | SAB Biotherapeutics Inc | 1,012,790 | 3.9M $ | |
| 14 | Orchestra BioMed Holdings Inc | 896,701 | 3.8M $ | |
| 15 | 4D Molecular Therapeutics Inc | 380,420 | 3.6M $ | |
| 16 | Ocular Therapeutix Inc | 382,375 | 3.2M $ | |
| 17 | Upstream Bio Inc | 341,779 | 3.1M $ | |
| 18 | Aquestive Therapeutics Inc | 710,988 | 3M $ | |
| 19 | EyePoint Inc | 215,825 | 2.8M $ | |
| 20 | Trevi Therapeutics Inc | 223,802 | 2.6M $ | |
| 21 | Zevra Therapeutics Inc | 282,418 | 2.6M $ | |
| 22 | IMMUNIC INC | 2,344,779 | 2.6M $ | |
| 23 | Coherus Oncology Inc | 1,420,550 | 2.4M $ | |
| 24 | Ovid therapeutics Inc | 921,457 | 2M $ | |
| 25 | Palisade Bio Inc | 1,115,000 | 2M $ | |
| 26 | KALARIS THERAPEUTICS INC | 295,771 | 1.7M $ | |
| 27 | LeonaBio Inc | 149,279 | 1.5M $ | |
| 28 | Nuvation Bio Inc | 329,296 | 1.4M $ | |
| 29 | Maze Therapeutics Inc | 43,798 | 1.3M $ | |
| 30 | Evommune Inc | 55,664 | 1.3M $ | |
| 31 | Corvus Pharmaceuticals Inc | 85,791 | 1.3M $ | |
| 32 | Aldeyra Therapeutics Inc | 730,606 | 1.2M $ | |
| 33 | Artiva Biotherapeutics Inc | 146,369 | 949.8K $ | |